Heska (NASDAQ:HSKA) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research downgraded shares of Heska (NASDAQ:HSKA) from a buy rating to a hold rating in a research report sent to investors on Tuesday, Zacks.com reports.

According to Zacks, “Heska Corporation sells advanced veterinary diagnostic and specialty products. Heska’s state-of-the-art offerings include blood testing instruments and supplies, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The Company’s core focus is on the canine and feline markets where it strives to provide high value products and unparalleled support to veterinarians. “

Other analysts have also recently issued research reports about the stock. BidaskClub upgraded shares of Heska from a hold rating to a buy rating in a research note on Tuesday, May 12th. Piper Sandler dropped their price objective on shares of Heska from $107.00 to $87.00 in a research note on Monday, May 25th. ValuEngine cut shares of Heska from a strong-buy rating to a buy rating in a research note on Thursday, April 2nd. Sidoti dropped their price objective on shares of Heska from $77.00 to $59.00 and set a neutral rating for the company in a research note on Friday, March 27th. Finally, TheStreet cut shares of Heska from a c- rating to a d+ rating in a research note on Friday, April 3rd. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus price target of $81.67.

Shares of HSKA stock opened at $91.16 on Tuesday. The company has a market capitalization of $843.77 million, a price-to-earnings ratio of -91.16 and a beta of 1.72. The company has a debt-to-equity ratio of 0.19, a quick ratio of 9.89 and a current ratio of 11.21. The company has a 50-day simple moving average of $85.53 and a 200 day simple moving average of $85.34. Heska has a 52 week low of $50.00 and a 52 week high of $110.90.

Heska (NASDAQ:HSKA) last announced its earnings results on Thursday, May 7th. The medical research company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.44). The company had revenue of $30.65 million for the quarter, compared to the consensus estimate of $33.47 million. Heska had a negative return on equity of 1.04% and a negative net margin of 5.99%. Sell-side analysts forecast that Heska will post -0.81 EPS for the current year.

In related news, CEO Kevin S. Wilson sold 1,734 shares of Heska stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $85.00, for a total transaction of $147,390.00. Following the sale, the chief executive officer now directly owns 108,221 shares of the company’s stock, valued at approximately $9,198,785. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kevin S. Wilson sold 3,266 shares of Heska stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $85.00, for a total transaction of $277,610.00. Following the sale, the chief executive officer now directly owns 104,955 shares in the company, valued at $8,921,175. The disclosure for this sale can be found here. Insiders sold a total of 30,941 shares of company stock valued at $2,741,842 over the last 90 days. Corporate insiders own 11.70% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Fred Alger Management LLC boosted its stake in shares of Heska by 3.5% in the 1st quarter. Fred Alger Management LLC now owns 1,079,219 shares of the medical research company’s stock valued at $59,681,000 after purchasing an additional 36,907 shares during the last quarter. FMR LLC lifted its position in shares of Heska by 2.0% during the 1st quarter. FMR LLC now owns 453,664 shares of the medical research company’s stock valued at $38,616,000 after acquiring an additional 8,870 shares during the period. Nine Ten Capital Management LLC lifted its position in shares of Heska by 1.2% during the 1st quarter. Nine Ten Capital Management LLC now owns 338,862 shares of the medical research company’s stock valued at $18,739,000 after acquiring an additional 4,178 shares during the period. State Street Corp lifted its position in shares of Heska by 1.2% during the 1st quarter. State Street Corp now owns 287,309 shares of the medical research company’s stock valued at $15,888,000 after acquiring an additional 3,430 shares during the period. Finally, Grandeur Peak Global Advisors LLC lifted its position in shares of Heska by 89.9% during the 1st quarter. Grandeur Peak Global Advisors LLC now owns 138,756 shares of the medical research company’s stock valued at $7,673,000 after acquiring an additional 65,700 shares during the period. 79.78% of the stock is currently owned by hedge funds and other institutional investors.

About Heska

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.

Recommended Story: Fundamental Analysis – How It Helps Investors

Get a free copy of the Zacks research report on Heska (HSKA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.